NCT05646758 2024-03-18
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
Clinical Trials
55 trialsNCT05346198 2024-02-23
Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Unknown
NCT05308875 2024-01-05
Efficacy and Safety Evaluation of PD1-BCMA-CART
Bioray Laboratories
Phase NA Unknown
NCT06126237 2023-11-13
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2 Unknown
NCT04519476 2023-10-31
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
Oncotherapeutics
Phase 1 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06067581 2023-10-05
the Safety and Efficacy of SENL103 Autologous T Cell Injection
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05920876 2023-06-27
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03090659 2023-06-12
LEGEND-2
Nanjing Legend Biotech Co.
Phase 1/2 Unknown
NCT05271682 2023-05-16
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT04272151 2023-04-18
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04861480 2023-04-18
Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT04674514 2023-03-07
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04309084 2023-02-16
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
Phase 1 Unknown
NCT05698303 2023-01-26
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1 Unknown
NCT05007418 2023-01-17
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
Sorrento Therapeutics, Inc.
Phase 1 Unknown
NCT05652530 2022-12-15
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
Shenzhen Pregene Biopharma Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05619861 2022-11-17
CAR-T Cells in the Treatment of Malignant Hematological Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT04688853 2022-09-08
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients
Gadeta B.V.
Phase 1 Unknown
NCT05478343 2022-07-28
Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05236621 2022-02-11
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05066646 2021-11-23
FUMANBA-1
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT04818372 2021-11-12
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
Keymed Biosciences Co.Ltd
Phase 1 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04003168 2021-03-01
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase 1 Unknown
NCT04665076 2020-12-11
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04447573 2020-09-29
Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown
NCT04275583 2020-06-17
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT03051841 2020-02-24
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Chong Kun Dang Pharmaceutical
Phase 1 Unknown
NCT03150316 2020-02-24
CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma
Chong Kun Dang Pharmaceutical
Phase 1 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04186052 2019-12-04
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04156269 2019-11-12
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT02387879 2019-09-26
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
Celgene
Unknown
NCT03018405 2019-09-19
THINK
Celyad Oncology SA
Phase 1/2 Unknown
NCT03618602 2019-09-19
Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Shanghai Theorion Pharmaceutical Co Ltd.
Phase 1 Unknown
NCT03999697 2019-06-27
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1 Unknown
NCT03661554 2018-09-10
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Phase EARLY_PHASE1 Unknown
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT03559764 2018-06-18
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02303353 2017-02-24
Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy
SPGO Research Mannheim GmbH
Unknown
NCT02916420 2016-11-02
Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT01522872 2016-06-02
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Threshold Pharmaceuticals
Phase 1/2 Unknown
NCT02240537 2016-04-19
BBMPI03
Benovus Bio, Inc.
Phase 1 Unknown
NCT01435720 2014-09-11
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Senesco Technologies, Inc.
Phase 1/2 Unknown
NCT00423644 2013-11-14
A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b
Alaunos Therapeutics
Phase 2 Unknown
NCT01695590 2013-06-04
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Prolexys Pharmaceuticals
Phase 1/2 Unknown
NCT01572688 2012-08-02
MM
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase NA Unknown